| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $3.6M | — | -29.8% |
| SG&A Expense | $1.0M | — | -23.1% |
| Operating Income | -$4.7M | — | +28.4% |
| Net Income | -$5.3M | — | +15.2% |
| EPS (Basic) | -$0.16 | — | +23.8% |
| EPS (Diluted) | -$0.16 | — | +23.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $10.9M | -17.2% | -71.0% |
| Short-term Investments | $11.2M | +0.0% | +11.6% |
| Current Assets | $14.1M | -48.2% | -71.3% |
| Total Assets | $27.1M | -12.0% | -45.0% |
| Current Liabilities | $9.1M | -4.3% | -6.1% |
| Total Liabilities | $9.1M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.5M | — | -543.7% |
| Investing Cash Flow | $2.3M | — | +122.6% |
| Financing Cash Flow | $20.0M | — | +0.0% |
| -28.3% |
| Stockholders' Equity | $18.0M | -15.5% | -50.8% |